In this work, we focused on HER-2-positive breast cancer since the amplification of HER-2 occurs approximately in 15–20% of the cases and is correlated with a higher grade, a more aggressive phenotype, and a worse prognosis [10]. Here, ERBB2 is linked to breast carcinoma.